A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36) Meeting Abstract
| Authors: | Rasco, D. W.; Bendell, J. C.; Wang-Gillam, A.; Park, W.; O'Reilly, E. M.; Zhou, L.; Galkin, A.; Carter, L. L.; Nickle, D.; Li, J.; Ferguson, B.; Chaney, M. F.; Dupont, J.; Messersmith, W. A. |
| Abstract Title: | A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368301341 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.3085 |
| Notes: | Meeting Abstract: 3085 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
